JMP Securities Defends Retrophin, Believes It's Well Positioned To Defend Thiola Franchise From Imprimis Pharma Competition

By: via Benzinga
JMP Securities’ Lisa A Bayko maintained a Market Outperform rating for Retrophin Inc. (NASDAQ: RTRX), with a price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.